Duloxetine updated on 07-01-2025

Small for gestational age (weight)

id	Study   Auto Martin - Norway, 2024Martin - UK, 2024Ankarfeldt (Controls unexposed, NOS), 2023Ankarfeldt (Controls unexposed, sick), 2023Huybrechts (Controls unexposed, NOS), 2020	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimesterPaternal exp. genotoxic window only (0–3 months preconception)Paternal exposure: epigenetic window only (3–xxx months preconception)Paternal exposure: genotoxic/epigenetic window (0–xxx months preconception)Paternal exposure: other window	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedsiblingwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S18347 R77388	Martin - Norway, 2024	Small for gestational age (SGA, defined as those with a birth weight in the lowest 10 percentiles for gestational age (<10th percentile)	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed (general population or NOS)	Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...)	1.35 [0.77;2.35]	15/101   65,372/662,309	65,387	101		ref
S18346 R77385	Martin - UK, 2024	Small for gestational age (SGA, defined as those with a birth weight in the lowest 10 percentiles for gestational age (<10th percentile)	during pregnancy (anytime or not specified)	population based cohort retrospective	unexposed (general population or NOS)	Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...)	0.59 [0.21;1.64]	4/56   23,198/330,696	23,202	56		ref
S15180 R62309	Ankarfeldt (Controls unexposed, NOS), 2023	Small for gestational age (SGA, birth weight under the tenth percentiles stratified on pregnancy week and sex)	late pregnancy	population based cohort retrospective	unexposed (general population or NOS) excluded	Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...)	0.75 [0.53;1.06] excluded (control group)	36/450   187,611/2,082,019	187,647	450		ref
S15181 R62313	Ankarfeldt (Controls unexposed, sick), 2023	Small for gestational age (SGA, birth weight under the tenth percentiles stratified on pregnancy week and sex)	late pregnancy	population based cohort retrospective	unexposed, sick	Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy)	0.81 [0.56;1.18]	36/450   343/3,772	379	450		ref
S11747 R43160	Huybrechts (Controls unexposed, NOS), 2020	Small for gestational age (ICD-9 codes 656.5x, 764.0x, 764.1x, and 764.9x)	late pregnancy	retrospective cohort (claims database)	unexposed (general population or NOS)	Adjustment: Yes Monotherapy: no or not specified	1.20 [0.83;1.72]	29/880   27,762/1,364,101	27,791	880		ref
					Total	4 studies	1.01 [0.76;1.36]		116,759	1,487
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 15180